Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06141473 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,600
- Enrollment target
- 20
- Study locations
NCT06141473 is a Phase 3 study of Multiple Sclerosis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 1,600 participants, above the 580-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (176% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06141473, a Phase 3 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will have variable duration depending on the recruitment rate, the event rate, the study discontinuation rate and the 12-month minimum treatment duration. Different participants will have different study durations. The last participant randomized will have at least 12 months of study duration, and assuming a 28-month recruitment period, the first participant randomized will have 40 months or longer of study duration. * The study intervention duration will vary similarly as the study duration. * The assessment of scheduled visits will include 1 common end of study \[EOS\] visit and 3 follow-up visits) with a visit frequency of every 4 weeks for the first 6 months and then every 3 months.
Conditions Studied
Interventions
- DRUG Frexalimab
- DRUG Teriflunomide
- DRUG Placebo infusion
- DRUG Placebo tablet
- DRUG MRI contrast-enhancing agents
Study Locations (20)
California
- The Neurology Center of Southern California - Carlsbad- Site Number : 8400023 - Carlsbad
- University of California Irvine - School of Medicine- Site Number : 8401143 - Irvine
- Multiple Sclerosis Center of California - Laguna Hills- Site Number : 8401122 - Laguna Hills
- Chemidox Clinical Trials- Site Number : 8401157 - Lancaster
- Hoag Memorial Hospital Presbyterian- Site Number : 8401031 - Newport Beach
- Private Practice - Dr. Regina Berkovich- Site Number : 8400005 - West Hollywood
Alabama
- University of Alabama at Birmingham- Site Number : 8401135 - Birmingham
- North Central Neurology Associates- Site Number : 8401100 - Cullman
- Alabama Neurology Associates- Site Number : 8400115 - Homewood
Arizona
- St. Joseph's Hospital and Medical Center- Site Number : 8401139 - Phoenix
- Perseverance Research Center- Site Number : 8401138 - Scottsdale
- Clinical Endpoints- Site Number : 8400050 - Scottsdale
Florida
- Neurology of Central Florida- Site Number : 8401147 - Altamonte Springs
- Neurology Offices of South Florida - Boca Raton- Site Number : 8401169 - Boca Raton
- First Choice Neurology - Espinosa Neuroscience Institute- Site Number : 8401071 - Boca Raton
Colorado
- University of Colorado - Anschutz Medical Campus- Site Number : 8401001 - Aurora
- Advanced Neurology of Colorado- Site Number : 8401148 - Fort Collins
Connecticut
- Hartford Healthcare Medical Group- Site Number : 8401069 - Norwich
- New England Institute for Clinical Research- Site Number : 8400114 - Stamford
District of Columbia
- MedStar Georgetown University Hospital- Site Number : 8400044 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2027-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06141473
The ClinicalTrials.gov registry entry for NCT06141473 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 580-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (176% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 5 interventions - of which Frexalimab is the first listed.
NCT06141473 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06141473 about?
NCT06141473 is a clinical study titled "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis". The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People ...
What is the current status of trial NCT06141473?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,600 participants. The study started on 2023-12-13. Estimated completion is 2027-05-06.
What conditions does trial NCT06141473 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06141473?
The interventions under investigation include: Frexalimab (DRUG), Teriflunomide (DRUG), Placebo infusion (DRUG), Placebo tablet (DRUG), MRI contrast-enhancing agents (DRUG).
Who is sponsoring clinical trial NCT06141473?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06141473 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.